Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome

Blood Adv. 2022 Sep 27;6(18):5477-5481. doi: 10.1182/bloodadvances.2022007128.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Janus Kinase 2 / genetics
  • Myeloproliferative Disorders* / genetics
  • Neoplasms*

Substances

  • Janus Kinase 2